Economic burden of atherosclerotic cardiovascular disease : a matched case–control study in more than 450,000 Swedish individuals
Steen Carlsson, Katarina LU
; Nilsson, Kristoffer
; Wolden, Michael Lyng
and Faurby, Mads
(2023)
In BMC Cardiovascular Disorders
23(1).
- Abstract
Aim: To examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden. Methods: Individuals aged ≥ 16 years living in Sweden on 01 January 2012 were identified in an existing database. Individuals with ASCVD were propensity score matched to controls without ASCVD by age, sex and educational status. We compared direct healthcare costs (inpatient, outpatient and drug costs), indirect costs (resulting from work absence) and the risk of stroke, myocardial infarction (MI) and early retirement. Results: After matching, there were 231,417 individuals in each cohort. Total mean per-person annual costs were over... (More)
Aim: To examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden. Methods: Individuals aged ≥ 16 years living in Sweden on 01 January 2012 were identified in an existing database. Individuals with ASCVD were propensity score matched to controls without ASCVD by age, sex and educational status. We compared direct healthcare costs (inpatient, outpatient and drug costs), indirect costs (resulting from work absence) and the risk of stroke, myocardial infarction (MI) and early retirement. Results: After matching, there were 231,417 individuals in each cohort. Total mean per-person annual costs were over 2.5 times higher in the ASCVD group versus the controls (€6923 vs €2699). Indirect costs contributed to 60% and 67% of annual costs in the ASCVD and control groups, respectively. Inpatient costs accounted for ≥ 70% of direct healthcare costs. Cumulative total costs over the 5-year period were €32,011 in the ASCVD group and €12,931 in the controls. People with ASCVD were 3 times more likely to enter early retirement than controls (hazard ratio [HR] 3.02 [95% CI 2.76–3.31]) and approximately 2 times more likely to experience stroke (HR 1.83 [1.77–1.89]) or MI (HR 2.27 [2.20–2.34]). Conclusion: ASCVD is associated with both economic and clinical impacts. People with ASCVD incurred considerably higher costs than matched controls, with indirect costs resulting from work absence and inpatient admissions being major cost drivers, and were also more likely to experience additional ASCVD events.
(Less)
- author
- Steen Carlsson, Katarina
LU
; Nilsson, Kristoffer
; Wolden, Michael Lyng
and Faurby, Mads
- organization
- publishing date
- 2023-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Atherosclerotic cardiovascular disease, Burden of illness, Direct costs, Indirect costs, Mortality
- in
- BMC Cardiovascular Disorders
- volume
- 23
- issue
- 1
- article number
- 483
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:37773098
- scopus:85173561827
- ISSN
- 1471-2261
- DOI
- 10.1186/s12872-023-03518-y
- language
- English
- LU publication?
- yes
- id
- 45f16690-e472-42b1-b8c1-8fa2ad4487aa
- date added to LUP
- 2023-12-05 14:47:01
- date last changed
- 2024-04-18 10:29:34
@article{45f16690-e472-42b1-b8c1-8fa2ad4487aa,
abstract = {{<p>Aim: To examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden. Methods: Individuals aged ≥ 16 years living in Sweden on 01 January 2012 were identified in an existing database. Individuals with ASCVD were propensity score matched to controls without ASCVD by age, sex and educational status. We compared direct healthcare costs (inpatient, outpatient and drug costs), indirect costs (resulting from work absence) and the risk of stroke, myocardial infarction (MI) and early retirement. Results: After matching, there were 231,417 individuals in each cohort. Total mean per-person annual costs were over 2.5 times higher in the ASCVD group versus the controls (€6923 vs €2699). Indirect costs contributed to 60% and 67% of annual costs in the ASCVD and control groups, respectively. Inpatient costs accounted for ≥ 70% of direct healthcare costs. Cumulative total costs over the 5-year period were €32,011 in the ASCVD group and €12,931 in the controls. People with ASCVD were 3 times more likely to enter early retirement than controls (hazard ratio [HR] 3.02 [95% CI 2.76–3.31]) and approximately 2 times more likely to experience stroke (HR 1.83 [1.77–1.89]) or MI (HR 2.27 [2.20–2.34]). Conclusion: ASCVD is associated with both economic and clinical impacts. People with ASCVD incurred considerably higher costs than matched controls, with indirect costs resulting from work absence and inpatient admissions being major cost drivers, and were also more likely to experience additional ASCVD events.</p>}},
author = {{Steen Carlsson, Katarina and Nilsson, Kristoffer and Wolden, Michael Lyng and Faurby, Mads}},
issn = {{1471-2261}},
keywords = {{Atherosclerotic cardiovascular disease; Burden of illness; Direct costs; Indirect costs; Mortality}},
language = {{eng}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{BMC Cardiovascular Disorders}},
title = {{Economic burden of atherosclerotic cardiovascular disease : a matched case–control study in more than 450,000 Swedish individuals}},
url = {{http://dx.doi.org/10.1186/s12872-023-03518-y}},
doi = {{10.1186/s12872-023-03518-y}},
volume = {{23}},
year = {{2023}},
}